Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation Of The Efficacy of a Strain-Specific Probiotic Formulation in Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03066921
Recruitment Status : Completed
First Posted : March 1, 2017
Last Update Posted : January 11, 2018
Sponsor:
Information provided by (Responsible Party):
Paik Seong Lim, Tungs' Taichung Metroharbour Hospital

Brief Summary:
Previous studies found that lactic acid bacteria could inhibit the activity of the performance of aristolochic acids (AAs) and improve apoptosis of proximal tubular epithelial cells (NRK-52E) and renal fibrosis on rats. The aim of this study is to assessment a novel health food of lactic acid bacteria for preventing renal dysfunction and replacing or assisting conventional drug treatment. This study in 300 hemodialysis patients with dialysis quality assessment index (KT/V, urea reduction ratio (URR), albumin, prealbumin, Hb, CRP…) screened for more than three months, and the stability of the situation in dialysis patients. They will be divided into two groups in order to conduct ergonomic assessments. One group maintains their original diet and medicine. The other group will take the novel lactic acid bacteria and placebo (1x1011 cfu/3±0.2 g/bag) in every morning and evening after their meals. The effect of 0, 6, 12, 18, 24 weeks of the novel lactic acid bacteria will be assessed after starvation for 4 weeks. Group C was the control group did not give any test samples, but continued to observe. The overall goal of the aforementioned study is to develop a novel food product of lactic acid bacteria which can improve dialysis quality for hemodialysis patients. The investigators hope that this novel product can get a patent and be commercialized.

Condition or disease Intervention/treatment Phase
End Stage Renal Disease Dietary Supplement: Probiotic packet Dietary Supplement: Placebo Not Applicable

Detailed Description:

Background:

Insulin resistance (IR) and its associated metabolic disorders are common features of chronic kidney disease (CKD)and accumulating evidence suggested they are important contributors for the cardiovascular burden of CKD patients. In recent years, the modification of the intestinal flora and activation of inflammation pathways have been implicated in the pathogenesis of IR in patients suffering from metabolic syndrome. These important discoveries have led to major advances in understanding the mechanisms of uraemia-induced IR. Furthermore, recent studies show impairment of the intestinal barrier and renal function function as well as changes in the composition of the gut microbiome can contribute to the prevailing inflammation, and gut-derived uremic toxins. Some of these uraemic toxins have been linked to the pathogenesis of IR.

Probiotics is one of the functional foods believed to mediate their health promoting activities through modulating the composition of the gut health. Ingestion of probiotics has been shown not only to influence gut microbiota composition but also the secretion of the gut hormones that ameliorate insulin resistance in animal models. Limited trials in human also showed that supplementation with probiotic not only affect glucose homeostasis, but improved other diabetes related comorbidities such as metabolic syndrome, hypertension, and hyperlipidemia. It also increasing clear that many of the multifactorial physiological functions of gut bacteria are highly strain specific, preselection of appropriate probiotic strains based on their expression of functional biomarkers is critical

Objectives and hypotheses:

To address this research gap, this randomized controlled trial is proposed to determine the efficacy of probiotic formulation to improve metabolic profile and reduction of uremic toxins through modulating gut microbiota composition and gut immune function in hemodialysis patients.The investigators hypothesized that the probiotic supplementations will improve blood glucose control as well as other related metabolic aberrations and lower the levels of gut-derived uremic toxins.

Methodology:

This is a single center, double blind randomized parallel group control trial with 6 months probiotic formulation with strain specific lactobacillus or placebo. After screening the eligible subjects will be selected. Then, after consent taking and 4 weeks of washout period, participants will be randomly assigned to either receive probiotic formulation or placebo for 6 months. Measurements of blood parameters including glycemic control related parameters, lipid profile, nutritional markers, inflammatory markers and uremic toxins. Nutritional assessments, quality of life assessment and anthropometry measurements will take place at baseline, and after 24 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized placebo controlled trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of the Effects of a Probiotic Formulation in Hemodialysis Patients
Actual Study Start Date : June 2016
Actual Primary Completion Date : October 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
Dietary Supplement: Placebo
Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).

Experimental: Probiotic packet
Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
Dietary Supplement: Probiotic packet
Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.




Primary Outcome Measures :
  1. Change from Baseline Triglyceride/HDL cholesterol ratio at 3 months, 6 months and 3 months after the trial [ Time Frame: baseline,3 months, 6 months and 3 months after the trial ]
    Plasma triglycerides are measured by enzymatic methods. High-density lipoprotein (HDL) cholesterol is measured in the supernatant after sodium phosphotungstate/magnesium chloride precipitation.


Secondary Outcome Measures :
  1. Plasma concentrations of typical gut-derived uremic toxins(Indoxyl sulfate and p-cresyl sulfate) [ Time Frame: baseline,3 months, 6 months and 3 months after the trial ]
    All uremic toxins are measured by a high performance liquid chromatography method and fluorescence detection method.

  2. plasma concentrations of inflammatory biomarkers [ Time Frame: baseline,3 months, 6 months and 3 months after the trial ]
    Interleukin-6 (IL-6) level is measured by an immunoenzymatic method, and C reactive protein (CRP) levels is measured by an immunonephelometric method.

  3. plasma concentrations of microbial translocation biomarkers [ Time Frame: baseline,3 months, 6 months and 3 months after the trial ]
    LBP and sCD14 are measured using an enzyme-linked immunosorbent assay (ELISA).

  4. Quality of life [ Time Frame: baseline and 6 months ]
    Assessed with the Medical Outcomes Study Short Form 36-Item Health Survey (SF-36)

  5. Nutritional Status [ Time Frame: baseline and 6 months ]
    Assessment with Subjective Global Assesment(SGA) and Mini Nutritional Assessment (MNA)

  6. Gut function questionnaire as a measure of tolerability [ Time Frame: Symptoms during first month ]
    Questionnaire is used to assess the tolerability of the probiotic supplementation. Questionnaire includes questions on frequency and severity of flatulence and bloating, occurrence of diarrhea, frequency of defecation, and texture of feces using a stool chart.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Both sexes aged between 20-75 years.
  2. Received stable hemodialysis at least 3 months.
  3. Written informed consent.

Exclusion Criteria:

  1. patients with severe infections, severe heart disease and liver disease, malignancy, autoimmune disorders, severe malnutrition, or clinical conditions requiring oral nutrition supplements;
  2. Inability to follow protocol.
  3. patients with known gastro-intestinal disease (i.e.,inflammatory bowel disease,crohn's disease,ulcerative colitis)
  4. Use of antibiotics, prebiotics or probiotics and immunosuppression medications in the past 4 weeks
  5. Pregnancy or wishing/trying to get pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066921


Locations
Layout table for location information
Taiwan
Tungs' Taichung MetroHarbour Hospital
Taichung, Taiwan
Sponsors and Collaborators
Paik Seong Lim
Investigators
Layout table for investigator information
Principal Investigator: Paik Seong Lim, PhD Tungs' Taichung Metroharbour Hospital
Layout table for additonal information
Responsible Party: Paik Seong Lim, National Science Council, Tungs' Taichung Metroharbour Hospital
ClinicalTrials.gov Identifier: NCT03066921    
Other Study ID Numbers: 104012
First Posted: March 1, 2017    Key Record Dates
Last Update Posted: January 11, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Paik Seong Lim, Tungs' Taichung Metroharbour Hospital:
Lactic acid bacteria
dyslipidemia uremic toxins
Hemodialysis
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Renal Insufficiency